iQure Pharma Inc.

SKILLMAN, NJ · Founded 2019 · CIK 0001996977 · Biotech · Private

Small molecule therapeutics targeting astrocyte glutamate regulation to treat CNS excitotoxicity

iqurepharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.3M
5 Form D · Jun 2026
4 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,500,000
Private capital raisedForm D · SEC$220,000
Private capital raisedForm D · SEC$1,443,786
Private capital raisedForm D · SEC$1,503,320
Private capital raisedForm D · SEC$650,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1688AscentX Medical, Inc.—$3.3M
1689Revolve Biotechnologies, Inc.——
1690MPEX PHARMACEUTICALS, INC.——
1691iQure Pharma Inc.—$5.3M
1692MicroMGx, Inc.——
1693AEON RESPIRE, INC.——
1694NEMUCORE MEDICAL INNOVATIONS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Pawel ZolnierczykExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.